title: Usefulness of CV 205-502 in a case of allergy to ergot-derived drugs.
abstract: This study reports a case of allergy to ergot-derived drugs in a patient with a prolactin (PRL)-secreting microadenoma. The anamnesis revealed allergic reactions to the administration of analgesics and antibiotics. The administration of dopamine agonist drugs, such as bromocriptine (BRC; 2.5 mg) or lisuride (0.2 mg), induced after a few minutes the appearance of nausea, vomiting, postural hypotension, headache, edema of the glottis with dispnea and acroedema. The edemas disappeared a few hours after the administration of antihistaminic drugs while nausea, vomiting, postural hypotension and headache persisted for a few days. Therefore, the patient was tested with another dopamine agonist non-ergot-derived drug, quinagolide (CV 205-502), which did not cause side effects or allergic reactions. Furthermore, not only was the responsiveness to the drug optimal but it also normalized the PRL levels, and menses reappeared after more than a 5-year amenorrhea. This report suggests that ergot-derived drugs, such as lisuride and BRC, seldom induce allergic reactions apart from common side effects. Consequently, the feasibility of using a new drug with a different molecular structure (non-ergot derived) effective in the therapy of hyperprolactinemic syndromes represents a good alternative to conventional therapy.
authors.affiliation: Cattedra di Endocrinologia, II Facoltà di Medicina e Chirurgia, Università di Napoli, Italia.
authors.forename: B
authors.initials: B
authors.lastname: Merola
authors.forename: F
authors.initials: F
authors.lastname: Sarnacchiaro
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: C
authors.initials: C
authors.lastname: Di Somma
authors.forename: A
authors.initials: A
authors.lastname: Di Sarno
authors.forename: E
authors.initials: E
authors.lastname: Caruso
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
mesh_terms: D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D001971:Bromocriptine / Q000009:adverse effects*; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D008090:Lisuride / Q000009:adverse effects; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000188:drug therapy*
chemical_list: D000634:Aminoquinolines; D001971:Bromocriptine; C046650:quinagolide; D011388:Prolactin; D008090:Lisuride